446-61-7

Upstream product

• 641-49-6 1-fluoro-3-methoxy-2-nitrobenzene 
• 4920-80-3 3-methoxy-2-nitrobenzoic acid 
• 16554-47-5 3-methoxy-2-nitroaniline 
• 15865-57-3 2-nitro-3-methoxybenzoyl chloride 
• 385-01-3 2-nitro-3-fluorophenol 

Downstream Products

• 1026693-18-4 1-(2-Fluoro-6-methoxy-phenyl)-3-pentyl-urea 
• 113028-78-7 1-(2-fluoro-6-methoxyphenyl)piperazine 
• 928627-08-1 (E)-3-Ethoxy-N-(3-fluoro-2-methoxyphenyl)acrylamide 
• 1073437-70-3 4-chloro-N-(2-fluoro-6-methoxyphenyl)-3-nitrobenzenesulfonamide 
• 1261216-27-6 4-bromo-2- fluoro-6-methoxyaniline 
• 94977-59-0 2-methyl-4-hydroxybenzothiazole 
• 5304-19-8 4-methoxy-2-methylbenzo[d]thiazole 

Relevant academic research and scientific papers

PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR

Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS

A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Dibenzothiophene Sulfoximine as an NH3 Surrogate in the Synthesis of Primary Amines by Copper-Catalyzed C?X and C?H Bond Amination

Readily accessible dibenzothiophene sulfoximine is an NH3 surrogate allowing the preparation of free anilines by copper-catalyzed cross-coupling reactions with aryl iodides or amides followed by radical S?N bond cleavage. The one-pot/two-step r

Structure-activity relationship of a series of phenylureas linked to 4- phenylimidazole. Novel potent inhibitors of acyl-CoA:cholesterol O- acyltransferase with antiatherosclerotic activity. 2

In our continuing search to find systemically bioavailable ACAT (acyl- CoA:cholesterol O-acyl-transferase) inhibitors with more potent antiatherosclerotic effect than N-[2-(dimethylamino)-6-[3-(5-methyl-4- phenyl-1H-imidazol-1-yl)propoxy]phenyl]-N'-pentyl